Skip to main content
. 2021 Feb 8;5(2):342–348. doi: 10.1002/rth2.12475

FIGURE 1.

FIGURE 1

Summary of inhibitor testing outcomes by tolerance status. Flow diagram depicts inhibitor titer and anti–factor VIII (FVIII) IgG4 antibody testing results stratified by tolerance status and emicizumab regimen with or without intermittent FVIII infusions. There were no individuals with detectable anti‐FVIII IgG1 antibodies in this cohort and thus the IgG1 status is not included in the diagram